Mary Canning

Mary Canning has a comprehensive work experience in the field of venture capital and biotechnology. Mary started their career as a Medici Fellow at the University of Nottingham in 2004 and then joined Scottish Enterprise as a Senior Executive in 2005. In this role, they oversaw the life science portfolio for the Proof of Concept Programme, focusing on accelerating the commercialization of new technologies.

In 2010, Mary joined MRC Technology as a Business Manager, where they identified, protected, and exploited intellectual property generated by MRC Units and the MRCT Centre for Therapeutics Discovery. Mary held this position until 2013.

Following their time at MRC Technology, Mary joined Epidarex Capital in 2013 as an Associate. Mary then progressed to the role of Principal in 2019, and most recently became a Partner in January 2023. At Epidarex Capital, they played a crucial role in identifying investment opportunities in the life science and biotechnology sectors.

Alongside their role at Epidarex Capital, Mary also held director positions at Transine Therapeutics, Caldan Therapeutics, and LUNAC Therapeutics starting from 2019, 2021, and 2022 respectively. These positions allowed their to further contribute to the growth and development of innovative biotech companies.

Mary Canning obtained their PhD in Molecular Genetics from The University of Edinburgh between the years 1996 to 2000.